# TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

> **NCT05984511** · NA · RECRUITING · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 234 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatic Portal Vein Tumor Invasion
- Tumor Thrombus

## Interventions

- **PROCEDURE:** I-125 Seeds Brachytherapy in PVTT
- **PROCEDURE:** Transcatheter arterial chemoembolization
- **DRUG:** Atezolizumab plus Bevacizumab

## Key facts

- **NCT ID:** NCT05984511
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-30
- **Primary completion:** 2028-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984511, "TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05984511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*